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Summary
Objectives: This study aimed to assess the research invest-
ments made to UK institutions for all infectious disease
research and identify the direction of spend by institution.
Design: Systematic analysis. Databases and websites were
systematically searched for information on relevant studies
funded for the period 1997–2010.
Setting: UK institutions carrying out infectious disease
research.
Participants: None.
Main outcome measures: Twenty academic institutions
receiving greatest sum investments across infection are
included here, also NHS sites, Sanger Institute, Health
Protection Agency and the Medical Research Council.
We measured total funding, median award size, disease
areas and position of research along the R&D value chain.
Results: Included institutions accounted for £2.1 billion
across 5003 studies. Imperial College and University of
Oxford received the most investment. Imperial College
led the most studies. The Liverpool and London Schools
of Tropical Medicine had highest median award size,
whereas the NHS sites combined had many smaller studies.
Sum NHS funding appears to be declining over time, whilst
university income is relatively stable. Several institutions
concentrate almost exclusively on pre-clinical research. In
some areas, there is clearly a leading institution, e.g.
Aberdeen and mycology research or UCL and antimicro-
bial resistance.
Conclusion: UK institutions carry out research across a
wide range of infectious disease areas. This analysis can
identify centres of excellence and help inform future
resource allocation for research priorities. Institutions can
use this analysis for establishing expertise within their
groups, identifying external collaborators and informing
local research strategy.
Keywords
institutions, universities, NHS, infectious disease, funding,
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Introduction
Infectious diseases cause a high burden of poten-
tially avoidable morbidity and mortality, and place
substantial strain on the limited health budgets,
health systems and economies of countries world-
wide. Investment in research is vital to aid imple-
mentation of programmes and policy that will
reduce these burdens, and to develop new tools
such as vaccines, diagnostics and drugs. Given the
limited funding available, allocating investments
appropriately and strategically is of paramount
importance.
In recent years, the UK has been considered to be
the second leading investor in global health and
research and development (R&D) for neglected dis-
eases.1,2 Thus, the coverage and impact of the UK
research portfolio is of great consequence, both in
terms of infections within the UK, but also its
global health outputs. Research takes place in univer-
sity settings and clinical environments, and is also
carried out by governmental or independent institu-
tions such as Public Health England (formerly the
Health Protection Agency, HPA) and the Medical
Research Council.
The Research Investments in Global Health study
(ResIn, www.researchinvestments.org) has tracked
the investments made to UK institutions in infectious
disease research over a 14-year time period from 1997
to 2010. The analysis has demonstrated that around
one-third of the investments had a clear focus on
global health, and that the UK appears to have
strengths in pre-clinical research.3 The project has
since focused on describing topic-speciﬁc areas of
investment such as highlighting the investments
with colonial ties,4 and assessing the investments by
gender of the principal investigator.5
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Here, we analyse the type of investments made by
the UK institutions, and describe the funding
awarded to these institutions in terms of award size
and number across infectious disease, clinical spe-
cialty, type of science along the R&D pipeline, and
area of microbiology.
Methods
The analysis presented here focused on research
investments by public and philanthropic funding
organisations awarded to the UK institutions
between 1997 and 2010. The methods are based on
a preliminary study mapping funding for infectious
disease research and are described in further detail
elsewhere.3 Further information on methods and
lists of categories is openly available on the study
website (http://www.researchinvestments.org).
The overarching dataset was developed following
a detailed and systematic search of all the studies for
infectious disease research from the major sources of
public and charitable funding for infectious disease
research studies, including the Wellcome Trust,
Medical Research Council and other research coun-
cils, UK government departments, European
Commission, the Bill and Melinda Gates
Foundation, and other research charities. No private
sector (commercial) funding was included in this ana-
lysis as publicly available data were limited and con-
sidered to be under-representative.
We developed the dataset by (a) downloading all
data from the funder website and manually ﬁltering
the infectious disease studies; or (b) searching open
access databases on the funder website for infection-
related keyword terms; or (c) contacting the funder
directly and requesting details of their infection stu-
dies. Funders were identiﬁed through authors’ know-
ledge of the R&D landscape, contributors to the
National Research Register and systematic searches
of the Internet. Author MGH performed the majority
of data extraction, with support from author JRF.
Each study was assigned to as many primary disease
categories as appropriate. Within each category,
topic-speciﬁc sub-sections (including speciﬁc patho-
gen or disease) were documented. Studies were also
allocated to one of four R&D categories: pre-clinical;
phase 1, 2 or 3; product development; and implemen-
tation and operational research (including surveil-
lance, epidemiology and statistical and modelling
projects; see http://researchinvestments.org/data/ for
deﬁnitions and examples).
Universities receiving funding were categorised
individually, and the 20 academic institutions receiv-
ing greatest sum investments across infection are
included here. NHS hospitals and institutions
receiving funding were grouped into an ‘NHS’ cat-
egory. Other institutions classiﬁed separately and
also analysed here were the Sanger Institute, Health
Protection Agency (now Public Health England but
referred to as Health Protection Agency in this paper)
and the Medical Research Council (UK sites only,
units in Gambia and Uganda were excluded as they
were considered to be overseas institutions for the
purposes of this study). The University of London
colleges were considered separately: for example,
University College London (UCL), King’s College
London (KCL), and London School of Hygiene
and Tropical Medicine (LSHTM); the Liverpool
School of Tropical Medicine (LSTM) was considered
separately to the University of Liverpool.
Major funding organisations were categorised in
their own right, and smaller funding organisations
were grouped into categories, such as in-house uni-
versity funding, research charities and government
departments. A total of 26 funder categories were
used. Studies were excluded if: (i) they were not
immediately relevant to infection; (ii) they were vet-
erinary infectious disease research studies; (iii) they
concerned the use of viral vectors to investigate
non-communicable diseases; (iv) they were grants
for symposia or meetings or (v) they included UK
researchers, but with the funding awarded to and
administered through a non-UK institution.
Unfunded studies were excluded. Grants awarded in
a currency other than pounds sterling were converted
to UK pounds using the mean exchange rate in the
year of the award. All awards were adjusted for inﬂa-
tion and reported in 2010 UK pounds. Analysis was
carried out in Microsoft Excel and Access (versions
2000 and 2007) and Stata (versions 11, 12 and 13).
Results
We identiﬁed 6165 studies funded within the 14-year
study period and covering all infectious disease
research, representing an overall investment of £2.6
billion. In terms of total funding, the top 20 univer-
sities, plus the Sanger Institute, Health Protection
Agency, Medical Research Council and NHS
accounted for £2.1 billion across 5003 studies
(81.9% of the total funding and 82.5% of the stu-
dies). The remainder of the projects not analysed in
detail here were awarded to other academic institu-
tions such as the universities of York, Cardiﬀ and
Sheﬃeld, or other institutions types such as the
National Blood Service, National Institute for
Medical Research (NIMR) or Health Protection
Scotland. There were also 34 studies, representing
0.2% (£6.4 million) of total funding, where no insti-
tution was speciﬁed.
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Imperial College and University of Oxford
received the most investment, with Imperial College
awarded the greatest number of studies to a single
institution (Table 1). Other universities receiving par-
ticularly high levels of investment include LSHTM,
UCL and Glasgow. The LSTM also received high
levels of investment but the mean award size of
£1.5m (SD £4619005) was by far the greatest of any
institution and thus the total number of studies led by
LSTM were fewer than its peers. NHS institutions
received the fourth highest amount of investment,
and led on the most studies; the median award size
for NHS research was smaller than any of the other
institutions analysed (Table 1). The temporal invest-
ment awarded to the NHS for infectious disease
research appears to be declining (Figure 1a), whilst
university income for infection research is relatively
stable and perhaps increasing over time (Figure 1b).
In terms of the funding organisation (Table 1),
LSHTM and LSTM both received the greatest invest-
ment from the Bill and Melinda Gates Foundation,
who have made relatively few awards but have the
highest mean and median award size of all the fun-
ders.3 The Wellcome Trust was the leading investor
for 10 of the 24 institutions included here. The
Department of Health has been the main funder of
NHS-led research.
According to the type of science along the R&D pipe-
line (Table 2), many of the institutions focused heavily
on pre-clinical science, with Glasgow, Cambridge,
King’s College London (KCL), Birmingham, Dundee
and the Institute of Food Research all receiving greater
than 90% of their funding for basic science (Table 2).
The entirety of the investments made to the Sanger
Institute was funding for pre-clinical research. The
London and Liverpool schools of tropical medicine
and the NHS had a higher proportion of implementa-
tion and operational research in their portfolios than
most institutions. The only institution with greater
than 10% of their portfolio related to phase I–III clinical
trials was the Medical Research Council (56.0% of fund-
ing, 24.7% of studies); most institutions received little or
no funding for phase I–III clinical trials from public and
philanthropic funders.
In the area of microbiology (Table 3), Imperial
College received the greatest number of awards and
the highest total funding for bacteriology studies,
although Nottingham (67.9%) and Leicester
(75.5%) universities received the greatest proportion
of their total funding for bacteriology research.
Imperial and UCL received the greatest investments
for virology research, with UCL’s virology portfolio
totalling 61.2% of their investment received. The
Medical Research Council (84.7%) and KCL
(76.9%) also had a clear focus on virology research.
In terms of total investment, LSHTM and LSTM
focused primarily on parasitology research, whilst
Dundee (64.5%) also had a signiﬁcant investment in
this area. Aberdeen (64.8% of total funding) was the
sole university to have a dominant focus on mycology
research. The NHS focused on virology (47.1%) and
bacteriology (30.7%) studies, with smaller amounts
on mycology, parasitology and also prion research
(not reported here).
In consideration of the analysis by ‘the big three’
diseases of HIV, TB and malaria (Table 4), UCL
received greatest investments for HIV research,
though the NHS carried out more studies. HIV was
the focus of 20.1% of NHS funding. St Georges,
University of London (SGUL) had a proportionately
large HIV portfolio at their institution (56.1% of
total funding), as did KCL (68.2%). There was pro-
portionately less of a focus for tuberculosis research
across all institutions, with only Imperial College,
QMUL and Leicester receiving greater than 10% of
their total funding for tuberculosis studies (QMUL
the greatest proportion at 10.6%). The London and
Liverpool schools of tropical medicine and Oxford
carried out the most malaria-related research.
By cross-cutting theme (Table 5), the London
(85.6%) and Liverpool (96.5%) Schools of Tropical
Medicine had the greatest focus on global health.
University of Liverpool, Dundee and the Medical
Research Council also received greater than half of
their total investments for research related to global
health. Antimicrobial resistance has historically been
a neglected area of research,6 and only UCL (11.9%
of total funding across 24 studies) appears to have a
portfolio of any size at all in this area; the NHS
carried out 90 studies, but the total funding was
only £6.6 million. The NHS also carried out 208 stu-
dies in the area of diagnostics, but the total funding
was only £27.9 million; the other key institution in
this area was QMUL (£13.9 million, 43.9% of total
funding received). Oxford (£65.0 million, 24.2%) car-
ried out the most research related to vaccinology,
with SGUL (39.1% of total funding) also having a
proportionately greater focus in this area. The
Liverpool School of Tropical Medicine and the
Medical Research Council carried out the most
research into therapeutics.
Discussion
The top 20 universities plus selected other institutions
account for £2.1 billion of investment related to infec-
tious disease research across 5003 studies that were
awarded between 1997 and 2010. Imperial College
and Oxford received the most funding, and LSTM
received the highest mean and median awards
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(owing primarily to being awarded several large
grants from the Bill and Melinda Gates Foundation
for neglected tropical disease research). Many univer-
sities had a clear focus on pre-clinical research, whilst
the Medical Research Council focused on clinical
trials, and the London and the Liverpool Schools of
Tropical Medicine focused on implementation and
operational research. Several universities carried out
numerous studies on HIV, but few had a sizeable
portfolio relating to tuberculosis research, or for anti-
microbial resistance. The NHS has carried out
numerous studies across the R&D value chain, but
the amount of investment received by the NHS for
infection research appears to be declining.
This analysis is the most comprehensive descrip-
tion available of UK infectious disease research,
Figure 1. Investments for research awarded to the UK institutions over time and by type of science, showing research led by (a)
NHS institutions and (b) universities.
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providing a rigorous inspection of awards across
many institutions, many funders and many disease
areas; however, our study has several limitations.3
There were little publicly available data from the
pharmaceutical industry. Hence, there is a data gap
in relation to funding of clinical trials and develop-
ment of vaccines and diagnostics, which the pharma-
ceutical and biotechnology industries are typically
ﬁnancing. We rely on the original data being complete
and accurate, and are unable to take into account dis-
tribution of funds from the lead institution to colla-
borating partners, nor can we assess quantity of each
award given to overheads or the impact of the intro-
duction of full-economic costing. Institutions such as
the Sanger may also receive signiﬁcant capital invest-
ments which may be used to fund research and this
would not be captured here. Also, assigning studies to
categories is a subjective process – although we used
at least two researchers to do this to reduce inter-
observer error. Our study focuses on UK-led invest-
ments – we do not know if similar patterns (e.g. a
dominance of pre-clinical research and lack of public
or charitably-funded clinical trials) would also emerge
if the analysis is repeated for other high-income coun-
tries. We have not here measured either the outputs or
impact of funded research, nor assessed the value of
this research to the hosting institution.
UK investments for infectious disease research
overall show a broadly varied portfolio across disease
areas and type of science. Investments will often reﬂect
the research track record and local expertise; for exam-
ple, the UK schools of tropical medicine have clear
expertise in parasitology, and also within implementa-
tion research where skills such as executing oper-
ational and epidemiological activity are important
for carrying out the studies. Within the other leading
(in terms of total investment) universities, they gener-
ally have several leading research groups or discip-
lines; for example, Imperial has received funding for
many HIV studies, and with some overlap, they have
also conducted a portfolio of research into thera-
peutics relating to infectious disease. UCL received
less in the way of global health funding, though sub-
sequent to the time period of this analysis they have
made concerted eﬀorts to bolster their standing glo-
bally in both research and education.7 UCL also has a
large portfolio of HIV studies. Where universities had
a smaller total portfolio and possibly less capacity to
expand or compete in other topics, they often concen-
trated their eﬀorts in speciﬁc areas, such as mycology
research at Aberdeen, or Birmingham carrying out
almost entirely pre-clinical research (much of which
was related to infection-associated cancers).
There is a clear lack of public and philanthropic
funding being directed towards clinical trials (withT
a
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the exception of the Medical Research Council, where
much of the investment was directed through its
Clinical Trials Unit). Whilst the majority of invest-
ment will be sourced from the private sector in this
area, it may also be down to a cautious approach
from funders in that they will want a return on
their investment, and trials are often expensive and
methodologically diﬃcult to perform; if the trial is in
a low-income setting, then the diﬃculties may become
even greater. Thus, it may be that investments are
typically awarded to institutions that have a track
record in relation to the proposed piece of research,
and where the funder assumes a likelihood of ‘suc-
cess’ (however that may be deﬁned). UK investments
in global health and infectious disease have been
shown to follow previous colonial ties,4 and this
may in part be explained by adoption of the
English language and the presence of existing infra-
structure in these countries that UK institutions have
accessed previously (e.g. the Medical Research
Council units in Gambia and Uganda). There are
questions to be raised on whether a more ambitious
approach from funders might lead to further high-
impact research ﬁndings, and further help to improve
health outcomes and reduce inequalities in other geo-
graphical areas.
Beyond the universities and the NHS, there is
comparatively little in the way of research being led
by institutions such as the Sanger and the Health
Protection Agency. They collaborate on numerous
studies, but given the expertise, equipment and facil-
ities at the disposal of the Health Protection Agency
as a whole, it is perhaps disappointing that the Health
Protection Agency has not been able to initiate and
lead more research than is shown here.
There is a decrease in the temporal trend of total
investment by annum,3 although the ﬁgures here
show that universities’ income for infection research
is broadly stable and it is research investments in the
NHS that are particularly in decline. The NHS has
carried out research across the R&D value chain, and
again, given the expertise within the hospitals and
other healthcare facilities, government and policy
groups should consider how best to enable greater
quantities of research within these settings as the
NHS moves forward from its most recent and con-
tinuing reforms.
The UK has received signiﬁcant quantities of
investment to research a broad range of infectious
diseases along the R&D value chain from pre-clinical
to translational research. In order to better assess the
distribution of investments and research output glo-
bally, there is a need for funders and institutions in
other countries to provide similar and detailed infor-
mation on funded studies, and so build a global
research funding database; the World Health
Organisation is creating a global R&D observatory
to combine worldwide eﬀorts in this area.8 Our ana-
lysis could be used for analytical work to identify
gaps in research funding, reduce unnecessary dupli-
cation of research investments, prioritise health and
social policy decisions and help inform future
resource allocation for global research priorities.
Institutions can similarly use this analysis for estab-
lishing expertise within their groups, identifying
external collaborators and informing local research
strategy. Future research can describe updated
award data across greater numbers of institutions
and include multi-country analyses to identify how
research-active institutions in the UK compare with
international universities.
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